GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Catalyst Biosciences Inc (NAS:CBIO) » Definitions » 3-Year FCF Growth Rate

Catalyst Biosciences (Catalyst Biosciences) 3-Year FCF Growth Rate : 32.90% (As of Sep. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Catalyst Biosciences 3-Year FCF Growth Rate?

Catalyst Biosciences's Free Cash Flow per Share for the three months ended in Sep. 2023 was $-0.09.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 32.90% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 20.70% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 41.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Catalyst Biosciences was 79.60% per year. The lowest was -31.10% per year. And the median was 29.90% per year.


Competitive Comparison of Catalyst Biosciences's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Catalyst Biosciences's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Catalyst Biosciences's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Catalyst Biosciences's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Catalyst Biosciences's 3-Year FCF Growth Rate falls into.



Catalyst Biosciences 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Catalyst Biosciences  (NAS:CBIO) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Catalyst Biosciences 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Catalyst Biosciences's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Catalyst Biosciences (Catalyst Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
611 Gateway Boulevard, Suite 710, South San Francisco, CA, USA, 94080
Catalyst Biosciences Inc is a clinical-stage biopharmaceutical company. It mainly focuses on developing novel medicines to address serious medical conditions for individuals in need of treatment options. The company emphasizes product development efforts in the field of hemostasis and to develop valuable therapies for individuals with hemophilia. It is engaged in the clinical development of improved, next-generation subcutaneous prophylaxis using enhanced potency Factor VIIa and Factor IX variants.
Executives
Han Ying director 12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Charles C Wu director, officer: Chief Executive Officer 12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Songjiang Ma director, officer: President 12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Weiguo Ye officer: Chief Operating Officer 12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Renate Parry director 12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Ruoyu Chen officer: Interim CFO 12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Gordon Carmichael director 12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Gni Usa, Inc. 10 percent owner 12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Augustine Lawlor director 55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
Andrea Hunt director 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Seline E. Miller officer: SVP Finance; Interim CFO & PAO C/O REZOLUTE, INC., 1450 INFINITE DRIVE, LOUISVILLE CO 80027
Gni Hong Kong Ltd 10 percent owner 12/F ELITE CENTRE, 22 HUNG TO ROAD, KWUN TONG KL K3 0000
Gni Group Ltd. 10 percent owner NIHONBASHI-HONCHO YS BLDG 3F, 2-2-2 NIHONBASHI-HONCHO, CHUO-KU, TOKYO M0 103-0023
Thomas Wilson Eastling director 17520 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Ying Luo director NIHONBASHI-HONCHO YS BLDG 3F, 2-2-2 NIHONBASHI-HONCHO, CHUO-KU, TOKYO M0 103-0023